• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Tenon Medical Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket

    9/11/23 8:10:18 AM ET
    $AXLA
    $CRNX
    $HKIT
    $IMPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXLA alert in real time by email

    Tenon Medical, Inc. (NASDAQ:TNON) fell 34.3% to $0.1649 in pre-market trading as the company reported a proposed public offering of common stock.

    Axcella Health Inc. (NASDAQ:AXLA) fell 20.8% to $0.7762 in pre-market trading after jumping more than 70% on Friday.

    Courtside Group, Inc. (NASDAQ:PODC) shares fell 13% to $3.82 in pre-market trading after declining 45% on Friday.

    Impel Pharmaceuticals Inc. (NASDAQ:IMPL) shares fell 10% to $0.3788 in pre-market trading after gaining 10% on Friday.

    MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) fell 9.8% to $5.50 in pre-market trading.

    Nuwellis, Inc. (NASDAQ:NUWE) fell 8.3% to $1.76 in pre-market trading after gaining around 7% on Friday.

    Hitek Global Inc. (NASDAQ:HKIT) fell 8.2% to $2.92 in pre-market trading after dipping 25% on Friday.

    WANG & LEE GROUP, Inc. (NASDAQ:WLGS) fell 8.1% to $0.9283 in pre-market after surging around 22% on Friday.

    AEye, Inc. (NASDAQ:LIDR) shares fell 8% to $0.2252 in pre-market trading.

    Magenta Therapeutics, Inc. (NASDAQ:MGTA) fell 7.7% to $0.70 in pre-market trading.

     

    Now Read This: Oracle, Bowlero And 3 Stocks To Watch Heading Into Monday

    Get the next $AXLA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXLA
    $CRNX
    $HKIT
    $IMPL

    CompanyDatePrice TargetRatingAnalyst
    Crinetics Pharmaceuticals Inc.
    $CRNX
    1/12/2026$67.00Neutral → Buy
    Goldman
    AEye Inc.
    $LIDR
    9/8/2025$6.00Buy
    Alliance Global Partners
    Crinetics Pharmaceuticals Inc.
    $CRNX
    7/10/2025$36.00Neutral
    Goldman
    Crinetics Pharmaceuticals Inc.
    $CRNX
    3/25/2025$60.00Buy
    Stifel
    Crinetics Pharmaceuticals Inc.
    $CRNX
    2/11/2025Buy
    TD Cowen
    Crinetics Pharmaceuticals Inc.
    $CRNX
    2/4/2025Peer Perform
    Wolfe Research
    Crinetics Pharmaceuticals Inc.
    $CRNX
    1/22/2025$55.00Hold → Buy
    Jefferies
    Nuwellis Inc.
    $NUWE
    7/29/2024$17.00Buy
    ROTH MKM
    More analyst ratings

    $AXLA
    $CRNX
    $HKIT
    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Crinetics Pharmaceuticals upgraded by Goldman with a new price target

    Goldman upgraded Crinetics Pharmaceuticals from Neutral to Buy and set a new price target of $67.00

    1/12/26 7:47:46 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on AEye with a new price target

    Alliance Global Partners initiated coverage of AEye with a rating of Buy and set a new price target of $6.00

    9/8/25 9:28:50 AM ET
    $LIDR
    Auto Parts:O.E.M.
    Consumer Discretionary

    Goldman initiated coverage on Crinetics Pharmaceuticals with a new price target

    Goldman initiated coverage of Crinetics Pharmaceuticals with a rating of Neutral and set a new price target of $36.00

    7/10/25 8:53:33 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXLA
    $CRNX
    $HKIT
    $IMPL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Merriman D Jonathan bought $13,986 worth of shares (6,300 units at $2.22) (SEC Form 4)

    4 - PodcastOne, Inc. (0001940177) (Issuer)

    3/16/26 8:00:04 PM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    Director Merriman D Jonathan bought $12,688 worth of shares (6,100 units at $2.08) (SEC Form 4)

    4 - PodcastOne, Inc. (0001940177) (Issuer)

    12/18/25 5:00:04 PM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    Director Merriman D Jonathan bought $12,312 worth of shares (5,700 units at $2.16) (SEC Form 4)

    4 - PodcastOne, Inc. (0001940177) (Issuer)

    12/8/25 5:30:50 PM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    $AXLA
    $CRNX
    $HKIT
    $IMPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Aminov Erez

    4 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

    4/1/26 5:00:00 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Liveone, Inc.

    4 - PodcastOne, Inc. (0001940177) (Issuer)

    3/25/26 9:00:02 PM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Merriman D Jonathan

    4 - PodcastOne, Inc. (0001940177) (Issuer)

    3/24/26 9:01:02 PM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    $AXLA
    $CRNX
    $HKIT
    $IMPL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AXLA
    $CRNX
    $HKIT
    $IMPL
    SEC Filings

    View All

    Hitek Announces 50-for-1 Share Consolidation

    XIAMEN, China, April 1, 2026 /PRNewswire/ -- HiTek Global Inc. (NASDAQ:HKIT) (the "Company"), an information technology consulting and solutions provider, announced today that it will effect a 50-for-1 share consolidation of its Class A ordinary shares, effective April 6, 2026 (the "Share Consolidation"), in order to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Beginning with the opening of trading on April 6, 2026, the Company's Class A ordinary shares will begin trading on the Nasdaq Capital Market on a split-adjusted basis under the same trading symbol, "HKIT," and a new CUSIP number, G45139113. On November 24, 2025, at the 2025 Annual General

    4/1/26 8:40:00 AM ET
    $HKIT
    Computer Software: Prepackaged Software
    Technology

    Univest Securities, LLC Announces Closing of $3 Million Registered Direct Offering for its Client Hitek Global Inc. (NASDAQ: HKIT)

    New York, March 31, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of approximately $3 million for its client Hitek Global Inc. (NASDAQ:HKIT) (the "Company"), a China-based information technology consulting and solutions service provider. Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an aggregate of 100,000,000 of the Company's Class A ordinary shares (the "Shares") (or pre-funded warrants in lieu thereof) at a

    3/31/26 5:00:00 PM ET
    $HKIT
    Computer Software: Prepackaged Software
    Technology

    Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone

    MINNEAPOLIS, March 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces continued momentum in its pediatric category, which is now the Company's largest and fastest-growing category and represents approximately 50% of total U.S. revenue. "Our pediatric category has become a meaningful and durable driver of growth, now accounting for approximately half of total revenue in 2025. This is a significant milestone as it both demonstrates the importance of the pediatric utilization of Aquadex, and the flexibility of the device across multiple patient demographics," said Nuwell

    3/31/26 8:30:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEF 14A filed by Nuwellis Inc.

    DEF 14A - Nuwellis, Inc. (0001506492) (Filer)

    4/2/26 5:01:21 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - Nuwellis, Inc. (0001506492) (Filer)

    4/1/26 4:45:27 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Hitek Global Inc.

    6-K - HiTek Global Inc. (0001742341) (Filer)

    4/1/26 8:45:01 AM ET
    $HKIT
    Computer Software: Prepackaged Software
    Technology

    $AXLA
    $CRNX
    $HKIT
    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXLA
    $CRNX
    $HKIT
    $IMPL
    Financials

    Live finance-specific insights

    View All

    TBL Team Boxing League Partners with LiveOne (Nasdaq: LVO) to Stream Live Events Across 200+ Countries

    NEW YORK, March 26, 2026 /PRNewswire/ -- Team Boxing League ("TBL") today announced a strategic partnership with LiveOne, Inc. (NASDAQ:LVO) to exclusively stream its live boxing events to audiences in more than 200 countries worldwide. This partnership marks a significant milestone in TBL's global expansion strategy, leveraging LiveOne's extensive reach of over 200 million viewers and more than 5 billion fan engagements to bring the league's innovative, team-based boxing format to a worldwide audience. The partnership also unlocks new monetization opportunities for TBL across su

    3/26/26 9:30:00 AM ET
    $LVO
    $PODC
    Restaurants
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    PodcastOne (Nasdaq: PODC) Renews Exclusive Rights and Distribution Agreement with A+E Networks for Podcasts Cold Case Files, I Survived, American Justice, City Confidential and Ancient Aliens

    LOS ANGELES, March 19, 2026 (GLOBE NEWSWIRE) -- PodcastOne (NASDAQ:PODC), a leading publisher and podcast sales network, announced today that it has extended its agreement with A+E Networks for the exclusive sales and distribution rights to five popular podcasts Cold Case Files, I Survived, American Justice, City Confidential and Ancient Aliens. "At PodcastOne we're a full scope podcasting network that operates with a white glove boutique agency philosophy allowing us to work closely with our partners to grow podcast audiences. We couldn't be prouder of the impact our relationship with A+E has had on translating their programming to podcast form, and we look forward to collaborating for y

    3/19/26 8:30:00 AM ET
    $PODC
    Computer Software: Programming Data Processing
    Technology

    LiveOne (Nasdaq: LVO) Raises 2026 Cost Savings Target from $5M to $7.5M ($3.5M Completed); Increases Payables Conversion Target from $11M to $13M+ at $7.50 per share ($5M Completed)

    Additional ~$1.5M CPS savings expected by year-endLaunching two new Fortune 500 B2B partnerships reaching 100M+ monthly subscribers~$5.7M remaining under share repurchase planAcquired 900k+ shares of PodcastOne (NASDAQ:PODC) LOS ANGELES, March 18, 2026 (GLOBE NEWSWIRE) -- LiveOne, Inc. (NASDAQ:LVO), a creator-first, music, entertainment and technology platform, today announced that it has increased its projected 2026 cost savings target to more than $7.5 million, driven by continued operational efficiencies and workforce optimization initiatives. The Company also expanded its payables conversion initiative to more than $13 million at $7.50 per share, further strengthening its balance shee

    3/18/26 8:45:00 AM ET
    $LVO
    $PODC
    Restaurants
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    $AXLA
    $CRNX
    $HKIT
    $IMPL
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXLA
    $CRNX
    $HKIT
    $IMPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 7:55:29 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 5:46:54 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AEye Inc.

    SC 13G/A - AEye, Inc. (0001818644) (Subject)

    11/14/24 4:10:34 PM ET
    $LIDR
    Auto Parts:O.E.M.
    Consumer Discretionary